The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis

Wang, Xuan; Zhang, Tongyangzi; Guo, Zizhen; Pu, Jincheng; Riaz, Farooq; Feng, Run; Fang, Xingxing; Song, Jing; Liang, Yuanyuan; Wu, Zhenzhen; Pan, Shengnan; Tang, Jianping

doi:10.3389/fphar.2021.693796

Cited by 27 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regular physical exercise (endurance training) may prove beneficial. Hydroxychloroquine has been mentioned in reviews as a possible treatment option for fatigue, but there is currently no evidence of statistically significant improvement [126].…”

Section: Systemic Symptomsmentioning

confidence: 99%

Sjögren’s syndrome

André

Böckle

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Sjögren's syndrome (SjS) is an autoimmune disease characterized by the triad of sicca symptoms, fatigue and pain. This diagnosis is usually made in women at the average age of 60 years. Diagnosis is made when sicca symptoms persist for more than three months, after the exclusion of possible differential diagnoses, and using the ACR/ EULAR 2016 classification criteria for SjS. Many organs can be affected in the course of this disease. Xerosis cutis and pruritus are the most common skin manifestations, followed by leukocytoclastic vasculitis and subacute cutaneous lupus erythematosus. In addition, SjS patients often have myoarthralgia and neuropsychiatric symptoms. In the long term, attention must be paid to the increased risk of cardiovascular disease and lymphoma. Due to the multiorgan involvement in SjS patients, interdisciplinary care is required.

show abstract

Section: Systemic Symptomsmentioning

confidence: 99%

Sjögren’s syndrome

André

Böckle

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

Section: Systemische Symptomeunclassified

“…Hydroxychloroquin wird in Übersichtsarbeiten als mögliche Therapie der Fatigue angeführt. Bisher konnte jedoch nicht nachgewiesen werden, dass es zu statistisch signifikanter Besserung führt[126].Eine rezente multizentrische klinische Studie mit Hydroxychloroquin zeigte eine Reduktion des AV-Block-Rezidivs um mehr als die Hälfte (von 18 % auf 7,4 %)[131]. Daher kann die Einnahme von Hydroxychloroquin während der Schwangerschaft von Ro/SS-A Antikörper-positiven Müttern zur Prophylaxe eines fetalen AV-Blocks erwogen werden.…”

unclassified

Sjögren‐Syndrom

André

Böckle

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Das Sjögren-Syndrom (SjS) ist eine Autoimmunerkrankung aus dem Formenkreis der Kollagenosen, die durch die Trias Sicca-Symptomatik, Fatigue und Schmerz charakterisiert ist. Die Diagnose wird meist bei Frauen und oft erst spät, im Alter von durchschnittlich 60 Jahren, gestellt. Bei mehr als drei Monate andauernder Sicca-Symptomatik, die durch andere Differenzialdiagnosen nicht erklärbar ist, können die ACR/ EULAR 2016 Klassifikationskriterien für das SjS angewendet werden, um die Diagnose zu stellen. Im Rahmen des SjS können viele Organe betroffen sein. Die Xerosis cutis und der Pruritus sind die häufigsten Hautmanifestationen. Oftmals werden eine leukozytoklastische Vaskulitis und ein subakut kutaner Lupus erythematodes bei SjS-Patienten diagnostiziert. Zusätzlich haben SjS-Patienten häufig Myoarthralgien sowie neuropsychiatrische Symptome. Langfristig muss auf das erhöhte Risiko für kardiovaskuläre Erkrankungen sowie Lymphome geachtet werden. Aufgrund der Beteiligung vieler Organe bei SjS-Patienten ist ein interdisziplinärer Behandlungsansatz

show abstract

“…The efficacy of hydroxychloroquine in SSDE has not been established. A 2021 systematic review and meta-analysis showed improvement in xerostomia, but did not show significant relief of ocular or other systemic symptoms [ 28 ]. Common side effects include retinal toxicity, with a risk of cardiac, gastrointestinal, dermatological, and neuromuscular adverse effects [ 29 ].…”

Section: Conventional Treatmentsmentioning

confidence: 99%

Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Chen²,

Chu-Bédard³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Sjögren’s syndrome is a chronic and insidious autoimmune disease characterized by lymphocyte infiltration of exocrine glands. Patients typically present with dry eye, dry mouth, and other systemic manifestations. Currently, the available molecules and drug-delivery systems for the treatment of Sjögren’s syndrome dry eye (SSDE) have limited efficacy since they are not specific to SSDE but to dry eye disease (DED) in general. The current treatment modalities are based on a trial-and-error approach using primarily topical agents. However, this approach gives time for the vicious cycle of DED to develop which eventually causes permanent damage to the lacrimal functional unit. Thus, there is a need for more individualized, specific, and effective treatment modalities for SSDE. The purpose of this article is to describe the current conventional SSDE treatment modalities and to expose new advances in ocular drug delivery for treating SSDE. A literature review of the pre-clinical and clinical studies published between 2016 and 2022 was conducted. Our current understanding of SSDE pathophysiology combined with advances in ocular drug delivery and novel therapeutics will allow the translation of innovative molecular therapeutics from the bench to the bedside.

show abstract

The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis

Cited by 27 publications

References 29 publications

Sjögren’s syndrome

Sjögren’s syndrome

Sjögren‐Syndrom

Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Contact Info

Product

Resources

About